In This Article:
Insulet Corporation PODD announced favorable RADIANT trial clinical data for its Omnipod 5 at the 18th International Conference on Advanced Technologies and Treatments for Diabetes (“ATTD”). Omnipod 5 is the only FDA-cleared, fully disposable pod-based automated insulin delivery ("AID") system. The RADIANT trial results demonstrate Omnipod 5 to be clinically efficient for people living with type 1 diabetes. The conference was held in Amsterdam, Netherlands.
PODD Stock’s Likely Trend Following the News
Following the announcement, PODD’s shares were flat at $265.82 at the after-market trading yesterday. The company’s solid innovation efforts and ongoing expansion of the Omnipod 5 platform are creating synergies. Henceforth, we expect the latest development to motivate market sentiment toward the PODD stock in the upcoming days.
Insulet has a market capitalization of $18.67 billion at present. Going by the Zacks Consensus Estimate, the company’s earnings are likely to increase 33% in 2025 on an 18.1% improvement in revenues.
About PODD’s RADIANT Trial
The RADIANT study is the first randomized controlled trial to evaluate the direct transition from multiple daily injections (“MDI”) to an AID system in adults and children with type 1 diabetes. The study also assessed the safety and efficacy of an AID system paired with an Abbott FreeStyle Libre 2 family sensor. This included 188 people aged 4 to 70 years with type 1 diabetes and HbA1c levels of 7.5% to 11%, all of whom were using MDI with Continuous Glucose Monitoring (“CGM”) for at least three months prior.
Participants began with an average HbA1c level of 8.1%. After three months, people who used the Omnipod 5 System improved their HbA1c by an average of 0.8% compared with those using MDI plus CGM, resulting in a final HbA1c of 7.2%. For those beginning with an HbA1c level above 8%, the benefit was even greater, with an improvement of 1% compared with MDI plus CGM. Hence, Omnipod 5 can reduce the risk of developing diabetes complications in the future, such as cardiovascular disease, kidney disease and eye problems.
Additionally, Omnipod 5 users spent an additional 5.4 hours per day with glucose levels in the target range (70-180mg/dL) compared with MDI plus CGM users. This was accompanied by significantly less time per day with high glucose levels and no increase in time spent with dangerously low glucose. No life-threatening acute events such as severe hypoglycemia or diabetes-related ketoacidosis were recorded in the three months.
Image Source: Zacks Investment Research